Biocon Share Price Dips 2.47%; Launches Liraglutide in the UK for Diabetes & Obesity

Biocon Limited has launched its GLP-1 peptide, Liraglutide, in the United Kingdom for the treatment of diabetes and obesity. The drug-device combination will be marketed under the brand names Liraglutide Biocon for diabetes (gVictoza®) and Biolide for chronic weight management (gSaxenda®).

On February 28, 2025, Biocon share price opened at ₹311.75, the same as its previous close of ₹311.85. At 10:54 AM, the share price of Biocon was trading at ₹304.15, down by 2.47% on the NSE.

Regulatory Approval and Market Entry

The launch follows approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., making Biocon the first generics company to secure approval for gLiraglutide in a major regulated market. This approval highlights Biocon’s capabilities in developing complex GLP-1 peptide formulations and strengthens its position in the pharmaceutical industry.

Siddharth Mittal, CEO and Managing Director of Biocon Limited, emphasised that this launch is a major milestone in the company’s efforts to make essential diabetes and obesity treatments more affordable and accessible. The availability of gLiraglutide in the U.K. is expected to benefit patients and healthcare providers by providing a cost-effective alternative.

Conclusion

GLP-1 therapies are projected to be a key growth driver for Biocon. The company plans to expand its reach into other European markets, the U.S., and select MoW (Markets of the World) geographies. Biocon also aims to enhance its pipeline of GLP-1 peptide products, reinforcing its leadership in this sector.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.